CS
PRQR icon

Credit Suisse’s ProQR Therapeutics PRQR Stock Holding History

Credit Suisse’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-18,390
Closed -$106K – 4293
2019
Q3 		$106K Buy
18,390
+2,240
+14% +$17.9K ﹤0.01% 3962
2019
Q2 		$147K Sell
16,150
-536
-3% -$6.32K ﹤0.01% 3895
2019
Q1 		$232K Sell
16,686
-36,072
-68% -$539K ﹤0.01% 3712
2018
Q4 		$833K Sell
52,758
-20,882
-28% -$383K ﹤0.01% 2921
2018
Q3 		$1.43M Sell
73,640
-25,000
-25% -$266K ﹤0.01% 2607
2018
Q2 		$720K Hold
98,640
– – ﹤0.01% 3240
2018
Q1 		$303K Buy
98,640
+17,890
+22% +$57.5K ﹤0.01% 3566
2017
Q4 		$260K Buy
+80,750
New +$290K ﹤0.01% 3675

Other funds holding PRQR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Credit Suisse's PRQR Position: Q4 2019 in Review

Credit Suisse sold out of ProQR Therapeutics (PRQR) in Q4 2019, closing a stake of 18,390 shares — an estimated $106K sold.

Credit Suisse first reported a position in PRQR in Q4 2017 and held it in 8 quarters. The position peaked at $1.43M in Q3 2018. 51 funds tracked by Wall St. Rank hold PRQR as of Q4 2019.

  • Credit Suisse reported no remaining ProQR Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Credit Suisse sold 18,390 ProQR Therapeutics shares in Q4 2019, an estimated $106K.
  • Credit Suisse first reported a position in ProQR Therapeutics in Q4 2017 and held it in 8 quarters.
  • Credit Suisse's ProQR Therapeutics position peaked at $1.43M in Q3 2018.
  • 51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2019.

Based on Credit Suisse's 13F filing for Q4 2019, filed 12 Feb 2020.